Linders, D. G.J. (author), Deken, M. M. (author), van Dam, M. A. (author), Wasser, M. N.J.M. (author), Voormolen, E. M.C. (author), Kroep, J. R. (author), van Dongen, G. A.M.S. (author), Vugts, D. (author), de Geus-Oei, L.F. (author) Background: Approximately 20% of invasive ductal breast malignancies are human epidermal growth factor receptor 2 (HER2)-positive. These patients receive neoadjuvant systemic therapy (NAT) including HER2-targeting therapies. Up to 65% of patients achieve a pathological complete response (pCR). These patients might not have needed surgery....
journal article 2023
